Background:

Danofloxacin mesylate (CP 76136-27) is a fluoroquinolone antibacterial for veterinary use.Target: AntibacterialDanofloxacin mesylate (CP 76136-27) is a synthetic antibacterial agent of the fluoroquinolone class, acts principally by the inhibition of bacterial DNA-gyrase, which is necessary for supercoiling of DNA to provide a suitable spatial arrangement of DNA within the bacterial cell. The minimum inhibitory concentration of danofloxacin against 90% (MIC90) of contemporary European and North American field isolates of Pasteurella haemolytica, Pasteurella multocida and Haemophilus somnus, the most important bacterial respiratory pathogens of cattle, is 0.125 μg/ml [1]. Danofloxacin mesylate (CP 76136-27) shows protective dose (PD50) of 0.38, 0.8, 2.42 mg/kg for P. multocida, E. coli and S. choleraesuis in in vivo mouse protection assay [2].

参考文献:
[1]. Giles, C.J., et al., Clinical pharmacokinetics of parenterally administered danofloxacin in cattle. J Vet Pharmacol Ther, 1991. 14(4): p. 400-10.
[2]. McGuirk, P.R., et al., Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine. J Med Chem, 1992. 35(4): p. 611-20.